vs
BYLINE BANCORP, INC.（BY）とMESA LABORATORIES INC（MLAB）の財務データ比較。上の社名をクリックして会社を切り替えられます
BYLINE BANCORP, INC.の直近四半期売上が大きい（$112.4M vs $65.1M、MESA LABORATORIES INCの約1.7倍）。BYLINE BANCORP, INC.の純利益率が高く（33.4% vs 5.6%、差は27.9%）。BYLINE BANCORP, INC.の前年同期比売上増加率が高い（9.0% vs 3.6%）。過去8四半期でBYLINE BANCORP, INC.の売上複合成長率が高い（6.4% vs 5.1%）
Byline Bankは米国イリノイ州シカゴに本社を置く銀行で、銀行持株会社Byline Bancorp, Inc.の主要子会社です。米国SBA 7(a)ローンプログラムの第4位の貸し手として、顧客に各種銀行サービスや融資ソリューションを提供しています。
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
BY vs MLAB — 直接比較
損益計算書 — Q1 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $112.4M | $65.1M |
| 純利益 | $37.6M | $3.6M |
| 粗利率 | — | 64.2% |
| 営業利益率 | — | 12.2% |
| 純利益率 | 33.4% | 5.6% |
| 売上前年比 | 9.0% | 3.6% |
| 純利益前年比 | 33.0% | 316.6% |
| EPS（希薄化後） | $0.83 | $0.65 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $65.1M | ||
| Q3 25 | $115.7M | $60.7M | ||
| Q2 25 | $110.5M | $59.5M | ||
| Q1 25 | $103.1M | $62.1M | ||
| Q4 24 | $104.7M | $62.8M | ||
| Q3 24 | $101.8M | $57.8M | ||
| Q2 24 | $99.4M | $58.2M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $3.6M | ||
| Q3 25 | $37.2M | $2.5M | ||
| Q2 25 | $30.1M | $4.7M | ||
| Q1 25 | $28.2M | $-7.1M | ||
| Q4 24 | $30.3M | $-1.7M | ||
| Q3 24 | $30.3M | $3.4M | ||
| Q2 24 | $29.7M | $3.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 12.2% | ||
| Q3 25 | 43.1% | 7.8% | ||
| Q2 25 | 35.2% | 5.1% | ||
| Q1 25 | 36.4% | 2.4% | ||
| Q4 24 | 38.6% | 9.2% | ||
| Q3 24 | 39.3% | 6.1% | ||
| Q2 24 | 40.4% | 9.6% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | 5.6% | ||
| Q3 25 | 32.1% | 4.1% | ||
| Q2 25 | 27.2% | 8.0% | ||
| Q1 25 | 27.4% | -11.4% | ||
| Q4 24 | 34.3% | -2.7% | ||
| Q3 24 | 29.8% | 5.9% | ||
| Q2 24 | 29.9% | 5.8% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.65 | ||
| Q3 25 | $0.82 | $0.45 | ||
| Q2 25 | $0.66 | $0.85 | ||
| Q1 25 | $0.64 | $-1.30 | ||
| Q4 24 | $0.68 | $-0.31 | ||
| Q3 24 | $0.69 | $0.63 | ||
| Q2 24 | $0.68 | $0.62 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $198.4M | $29.0M |
| 総負債低いほど良い | — | $68.4M |
| 株主資本純資産 | $1.3B | $186.7M |
| 総資産 | $9.9B | $434.8M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.37× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $29.0M | ||
| Q3 25 | $259.0M | $20.4M | ||
| Q2 25 | $218.3M | $21.3M | ||
| Q1 25 | $421.3M | $27.3M | ||
| Q4 24 | $563.1M | $27.3M | ||
| Q3 24 | $452.6M | $24.3M | ||
| Q2 24 | $730.5M | $28.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $186.7M | ||
| Q3 25 | $1.2B | $178.5M | ||
| Q2 25 | $1.2B | $172.5M | ||
| Q1 25 | $1.1B | $159.8M | ||
| Q4 24 | $1.1B | $155.2M | ||
| Q3 24 | $1.1B | $161.5M | ||
| Q2 24 | $1.0B | $150.7M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $434.8M | ||
| Q3 25 | $9.8B | $430.4M | ||
| Q2 25 | $9.7B | $435.7M | ||
| Q1 25 | $9.6B | $433.3M | ||
| Q4 24 | $9.5B | $433.3M | ||
| Q3 24 | $9.4B | $454.1M | ||
| Q2 24 | $9.6B | $440.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $18.8M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $18.0M |
| FCFマージンFCF / 売上 | — | 27.7% |
| 設備投資強度設備投資 / 売上 | — | 1.1% |
| キャッシュ転換率営業CF / 純利益 | — | 5.17× |
| 直近12ヶ月FCF直近4四半期 | — | $37.9M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $18.8M | ||
| Q3 25 | $38.3M | $8.2M | ||
| Q2 25 | $16.3M | $1.9M | ||
| Q1 25 | $27.1M | $12.7M | ||
| Q4 24 | $175.2M | $18.1M | ||
| Q3 24 | $19.8M | $5.3M | ||
| Q2 24 | $40.1M | $10.7M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $18.0M | ||
| Q3 25 | $38.0M | $7.1M | ||
| Q2 25 | $15.2M | $884.0K | ||
| Q1 25 | $25.0M | $11.9M | ||
| Q4 24 | $171.2M | $17.3M | ||
| Q3 24 | $19.1M | $3.5M | ||
| Q2 24 | $39.4M | $9.9M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 27.7% | ||
| Q3 25 | 32.8% | 11.7% | ||
| Q2 25 | 13.7% | 1.5% | ||
| Q1 25 | 24.3% | 19.2% | ||
| Q4 24 | 163.5% | 27.6% | ||
| Q3 24 | 18.8% | 6.0% | ||
| Q2 24 | 39.7% | 16.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 1.1% | ||
| Q3 25 | 0.3% | 1.8% | ||
| Q2 25 | 1.0% | 1.7% | ||
| Q1 25 | 2.0% | 1.2% | ||
| Q4 24 | 3.8% | 1.3% | ||
| Q3 24 | 0.6% | 3.1% | ||
| Q2 24 | 0.7% | 1.5% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 5.17× | ||
| Q3 25 | 1.03× | 3.32× | ||
| Q2 25 | 0.54× | 0.40× | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | 1.54× | ||
| Q2 24 | 1.35× | 3.17× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BY
セグメントデータなし
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
